UA102830C2 - Профилактика условно-патогенных инфекций у лиц со сниженным иммунитетом - Google Patents

Профилактика условно-патогенных инфекций у лиц со сниженным иммунитетом

Info

Publication number
UA102830C2
UA102830C2 UAA201008634A UAA201008634A UA102830C2 UA 102830 C2 UA102830 C2 UA 102830C2 UA A201008634 A UAA201008634 A UA A201008634A UA A201008634 A UAA201008634 A UA A201008634A UA 102830 C2 UA102830 C2 UA 102830C2
Authority
UA
Ukraine
Prior art keywords
immune
prevention
opportunistic infections
bifidobacterium
compromised subjects
Prior art date
Application number
UAA201008634A
Other languages
English (en)
Ukrainian (uk)
Inventor
Норберт Спренгер
Original Assignee
Нестек С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39111664&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA102830(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Нестек С.А. filed Critical Нестек С.А.
Publication of UA102830C2 publication Critical patent/UA102830C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Abstract

Изобретение относится к композиции, пригодной для применения в профилактике условно-патогенных инфекций у лиц со сниженным иммунитетом, которая содержит пробиотикилии фукозилированный олигосахарид, который выбран из группы, в которую входят 2' фукозиллактоза, 3' фукозиллактоза, дифукозиллактоза, лакто-N-фукопентаоза, лакто-N-фукогексаоза, фукозиллакто-N-гексаоза и фукозиллакто-N-неогексаоза. Изобретение также касается применения композиции как средства для профилактики условно-патогенных инфекций у лиц со сниженным иммунитетом.
UAA201008634A 2007-12-17 2008-12-08 Профилактика условно-патогенных инфекций у лиц со сниженным иммунитетом UA102830C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123390A EP2072052A1 (en) 2007-12-17 2007-12-17 Prevention of opportunistic infections in immune-compromised subjects
PCT/EP2008/066850 WO2009077352A1 (en) 2007-12-17 2008-12-05 Prevention of opportunistic infections in immune-compromised subjects

Publications (1)

Publication Number Publication Date
UA102830C2 true UA102830C2 (ru) 2013-08-27

Family

ID=39111664

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201008634A UA102830C2 (ru) 2007-12-17 2008-12-08 Профилактика условно-патогенных инфекций у лиц со сниженным иммунитетом

Country Status (18)

Country Link
US (2) US9217133B2 (ru)
EP (2) EP2072052A1 (ru)
CN (1) CN101909644A (ru)
AU (1) AU2008337646B2 (ru)
BR (1) BRPI0820837A2 (ru)
CA (1) CA2709396A1 (ru)
ES (1) ES2576642T3 (ru)
IN (1) IN2010DE04311A (ru)
MX (1) MX2010006690A (ru)
MY (1) MY185938A (ru)
PH (1) PH12010501367B1 (ru)
PL (1) PL2234627T3 (ru)
PT (1) PT2234627T (ru)
RU (1) RU2486910C2 (ru)
SG (1) SG186657A1 (ru)
UA (1) UA102830C2 (ru)
WO (1) WO2009077352A1 (ru)
ZA (1) ZA201005088B (ru)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2698374C (en) 2007-09-07 2018-04-03 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
EP2451462B1 (en) 2009-07-06 2017-09-06 Children's Hospital Medical Center Inhibiting inflammation with milk oligosaccharides
WO2011008086A1 (en) 2009-07-15 2011-01-20 N.V. Nutricia Mixture of non-digestible oligosaccharides for stimulating the immune system
BR112012000859B1 (pt) 2009-07-15 2021-08-03 N.V. Nutricia Uso de 2'-fucosilactose na fabricação de uma composição enteral
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
WO2011136637A1 (en) * 2010-04-27 2011-11-03 N.V. Nutricia Use of human milk oligosaccharides in infant nutrition
PL2563166T3 (pl) * 2010-04-27 2014-10-31 Nutricia Nv Stosowanie oligosacharydów mleka ludzkiego w żywieniu niemowląt
EP2576578B1 (en) 2010-06-01 2018-09-19 Glycom A/S Polymorphs of 2'-o-fucosyllactose and producing thereof
EP2465509A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
EP2455387A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465508A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
WO2012092160A2 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
NZ613165A (en) 2010-12-31 2015-02-27 Abbott Lab Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated fatty acids and uses thereof
US9763970B2 (en) 2010-12-31 2017-09-19 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
NZ612504A (en) 2010-12-31 2015-02-27 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
ES2708924T3 (es) 2010-12-31 2019-04-12 Abbott Lab Procedimientos de uso de oligosacáridos de la leche humana para mejorar la salud respiratoria de las vías respiratorias
EP3338784B1 (en) 2010-12-31 2020-07-22 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
US20120171166A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
SG192095A1 (en) 2011-02-10 2013-08-30 Nestec Sa Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
JP6129821B2 (ja) * 2011-05-13 2017-05-17 グリコシン リミテッド ライアビリティー カンパニー プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
MY187589A (en) 2011-06-20 2021-09-30 Heinz Co Brands H J Llc Probiotic compositions and methods
CN107595860A (zh) * 2011-07-22 2018-01-19 雅培制药有限公司 用于预防胃肠道损伤和/或促进胃肠道修复的低聚半乳糖
WO2013032674A1 (en) 2011-08-29 2013-03-07 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
RU2624233C2 (ru) * 2011-10-18 2017-07-03 Нестек С.А. Композиция для применения при стимуляции ангиогенеза в кишечнике, всасывания питательных веществ и переносимости энтерального питания, и/или при профилактике, и/или лечении воспалительных заболеваний кишечника, и/или при выздоровлении после повреждения кишечника и хирургического вмешательства
US9636367B2 (en) * 2011-10-18 2017-05-02 Nestec S.A. Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
MY168661A (en) * 2012-03-27 2018-11-28 Abbott Lab Methods for modulating cell-mediated immunity using human milk oligosaccharides
EP2708145B1 (en) * 2012-09-14 2016-05-04 Abbott Laboratories Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10165788B2 (en) * 2013-06-17 2019-01-01 The Regents Of The University Of California Methods and compositions for improved digestion of milk oligosaccharides
EP2815757A1 (en) * 2013-06-17 2014-12-24 Hestia Investments Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa
US10357506B2 (en) 2013-11-15 2019-07-23 Nestec S.A. Compositions for use in the prevention or treatment of URT infections in infants or young children at risk
EP3082828B1 (en) 2013-11-15 2022-03-02 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by c-section
ES2895380T3 (es) 2013-11-15 2022-02-21 Nestle Sa Composiciones para su uso en la prevención o tratamiento de la enterocolitis necrotizante en bebés y niños pequeños
US10568896B2 (en) 2013-11-19 2020-02-25 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
CN113331426A (zh) 2014-04-08 2021-09-03 雅培公司 使用人乳寡糖增强对病原体的粘膜先天免疫反应和/或检测的方法
BR112017008284A8 (pt) * 2014-10-24 2023-04-11 Evolve Biosystems Inc Bifidobactérias ativadas e métodos para uso das mesmas
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
CN106998775A (zh) * 2014-11-26 2017-08-01 雅培制药有限公司 具有RRR‑α‑生育酚、2’‑岩藻糖基乳糖和益生菌的婴儿配方
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
AU2016227595B2 (en) 2015-03-05 2020-08-27 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of otitis or bronchitis in infants or young children
CN107405354A (zh) * 2015-03-05 2017-11-28 格礼卡姆股份公司 治疗急性呼吸道感染的组合物和方法
EP3264921A1 (en) * 2015-03-05 2018-01-10 Nestec S.A. Compositions for use in improving stool consistency or frequency in infants or young children
DE202016008919U1 (de) 2015-03-05 2020-09-07 Société des Produits Nestlé S.A. Zusammensetzungen zur Verwendung bei der Prävention oder Behandlung von gastrointestinalen Infektionen/Entzündungen bei Säuglingen oder Kleinkindern
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
CN109414464A (zh) * 2016-03-11 2019-03-01 进化生物系统股份有限公司 用于改善肠道健康的短暂共生微生物
WO2017215721A1 (en) * 2016-06-15 2017-12-21 Glycom A/S Synthetic compositions comprising human milk oligosaccharides for use γν the prevention and treatment of disorders
WO2019031961A1 (en) 2017-08-11 2019-02-14 N.V. Nutricia OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
EP3583858A1 (en) * 2018-06-20 2019-12-25 DuPont Nutrition Biosciences ApS Compositions for treating or preventing gut barrier dysfunction
US11554131B2 (en) * 2018-05-31 2023-01-17 Glycom A/S Mixture of HMOs for treating autoimmune diseases
WO2020246583A1 (ja) * 2019-06-05 2020-12-10 森永乳業株式会社 組成物
JP2023502260A (ja) * 2019-11-20 2023-01-23 アボット・ラボラトリーズ クロストリジウム・ディフィシル感染症を治療する栄養組成物
CN112870233A (zh) * 2019-11-29 2021-06-01 内蒙古伊利实业集团股份有限公司 包含乳双歧杆菌与母乳低聚糖的组合物及其应用
US20230149432A1 (en) * 2020-04-03 2023-05-18 Inner Mongolia Yili Industrial Group Co., Ltd. Human Milk Oligosaccharides for Improving Resistance of Organism Against Staphylococcus Aureus Infection
CN114504109B (zh) * 2020-11-16 2024-02-09 内蒙古伊利实业集团股份有限公司 一种含乳双歧杆菌与母乳低聚糖的组合物及其应用
CN116195740A (zh) * 2021-11-30 2023-06-02 内蒙古伊利实业集团股份有限公司 可提升生物体对金黄色葡萄球菌感染抵御能力的益生元与益生菌组合物
WO2024013393A1 (en) * 2022-07-15 2024-01-18 Dsm Ip Assets B.V. Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+
WO2024068747A1 (en) * 2022-09-27 2024-04-04 Société des Produits Nestlé S.A. Uses of bifidobacterium longum transitional microorganism

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
DK0577903T3 (da) 1992-07-06 1998-04-06 Nestle Sa Antigastritisk middel
DE69227329T3 (de) * 1992-07-06 2003-01-23 Nestle Sa Milchbakterien
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6045854A (en) 1997-03-31 2000-04-04 Abbott Laboraties Nutritional formulations containing oligosaccharides
WO1999017788A1 (en) * 1997-10-06 1999-04-15 Abbott Laboratories Composition of treatment of candidiasis
US5902743A (en) * 1998-03-20 1999-05-11 Wisconsin Alumni Research Foundation Probiotic bifidobacterium strain
US20020019991A1 (en) * 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6841149B1 (en) * 1998-05-29 2005-01-11 Agri-King, Inc. Probiotic mixture intended for monogastric animals to control intestinal flora populations
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7101565B2 (en) * 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
CA2530437C (en) * 2003-06-23 2011-11-15 Nestec S.A. Nutritional formula for optimal gut barrier function
ES2314461T3 (es) * 2003-10-24 2009-03-16 N.V. Nutricia Composicion simbiotica para bebes.
EP1689348B1 (en) 2003-12-05 2013-05-15 Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
US7137361B2 (en) 2004-06-22 2006-11-21 Federal-Mogul World Wide, Inc. Cylinder head gasket with one-way coolant flow valve
EP1714660A1 (en) 2005-04-21 2006-10-25 N.V. Nutricia Uronic acid and probiotics
EP1776877A1 (en) * 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
AU2007225549B2 (en) * 2006-03-10 2012-09-27 N.V. Nutricia Use of non-digestable sacharides for giving an infant the best start after birth
US20100063002A1 (en) 2007-03-13 2010-03-11 Bernd Stahl Method of improving skills with a composition comprising non-digestible saccharide
US8197872B2 (en) * 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
EP2072052A1 (en) 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
PL2072053T3 (pl) * 2007-12-21 2013-02-28 Gervais Danone Sa Sposób zmniejszania obwodu brzucha przez podawanie bakterii bifidobacterium

Also Published As

Publication number Publication date
CA2709396A1 (en) 2009-06-25
US20100260720A1 (en) 2010-10-14
AU2008337646B2 (en) 2014-07-17
US9217133B2 (en) 2015-12-22
PH12010501367B1 (en) 2009-06-25
AU2008337646A1 (en) 2009-06-25
ZA201005088B (en) 2017-03-27
ES2576642T3 (es) 2016-07-08
RU2010129685A (ru) 2012-01-27
SG186657A1 (en) 2013-01-30
RU2486910C2 (ru) 2013-07-10
EP2234627B1 (en) 2016-05-25
MY185938A (en) 2021-06-14
MX315565B (ru) 2010-09-10
PT2234627T (pt) 2016-07-26
BRPI0820837A2 (pt) 2015-06-16
EP2072052A1 (en) 2009-06-24
EP2234627A1 (en) 2010-10-06
US20120308527A1 (en) 2012-12-06
MX2010006690A (es) 2010-09-10
PL2234627T3 (pl) 2016-12-30
CN101909644A (zh) 2010-12-08
IN2010DE04311A (ru) 2010-11-12
WO2009077352A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
UA102830C2 (ru) Профилактика условно-патогенных инфекций у лиц со сниженным иммунитетом
WO2009112361A3 (en) Synbiotic mixture
MY149913A (en) Synbiotic mixture
MY146595A (en) Probiotic bifidobacterium strains
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
IN2012DN01638A (ru)
Arumugam et al. Probiotics and synbiotics decrease postoperative sepsis in elective gastrointestinal surgical patients: a meta-analysis
MX2015007933A (es) Oligosacaridos de leche humana para mejorar sintomas de estres.
SG10201901259RA (en) Prebiotic formulations and methods of use
WO2008117266A3 (en) Probiotic bifidobacterium strains
MX2008006546A (es) Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria.
EP2315582A4 (en) PROBIOTIC COMPOSITION USEFUL FOR DIETETICAL INCREASE AND / OR TO COMBAT CONDITIONS OF DISEASE AND ADVERSE PHYSIOLOGICAL CONDITIONS
BR112013020312A2 (pt) composições simbióticas para restauração e reconstituição da microbiota intestinal
US20120128633A1 (en) Use of collinsella aerofaciens for reducing bloating
WO2010142952A3 (en) Antibodies
PL1773361T5 (pl) Kompozycje oparte na bakteriach probiotycznych i ich zastosowanie w profilaktyce i/lub leczeniu patologii i/lub zakażeń układu oddechowego oraz poprawie funkcji jelit
GB0625523D0 (en) In vivo imaging agents
PL2219658T3 (pl) Kompozycja oparta na bakteriach probiotycznych w połączeniu z prebiotykiem i jej zastosowanie w zapobieganiu i/lub leczeniu schorzeń oddechowych i/lub infekcji oraz do polepszenia funkcjonalności jelit
NZ598751A (en) Anti-obesity agent, anti-obesity food or beverage, glucose tolerance-ameliorating agent, and food or beverage for amelioration of glucose tolerance (bifidobacterium breve mcc1274 (ferm bpp-11175))
WO2010008491A3 (en) Lactose compositions with decreased lactose content
MY158310A (en) Prevention and treatment of allergic diarrhoea
RU2018139655A (ru) Бифидобактерии для увеличения безжировой массы тела
HK1146914A1 (en) Pharmaceutical compositions comprising l. acidophilus and bifidobacterium lactis for use in the treatment of functional bowel disorder
WO2011080396A3 (en) Probiotic bifidobacterial composition in accordance with secretor blood group status
WO2006046871A3 (en) Peri-operative composition comprising lactobacillus rhamnosus